USPTO serial 86418815
TOLERO PHARMACEUTICALS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jun 9, 2015
- Examiner
- BUSH, KAREN K
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with TOLERO PHARMACEUTICALS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
SUMITOMO DAINIPPON PHARMA CO., LTD.
OSAKA-SHI, OSAKA, JP
Other trademarks owned by SUMITOMO DAINIPPON PHARMA CO., LTD.
Lehi, UT
Lehi, UT
Lehi, UT
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Howard N. Aronson
Howard N. Aronson Lackenbach Siegel LLP1 Chase RdLackenbach Siegel BuildingScarsdale, NY 10583-4156Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 042 | Bacteriological research; Bacteriological research and testing; Biochemical research and development; Biological research; Biomedical research services; Biotechnology research; Chemical analysis; Chemical engineering; Chemical laboratories; Chemical research; Chemical, biochemical, biological and bacteriological research and analysis; Chemist services; Conducting clinical trials for others; Conducting early evaluations in the field of new pharmaceuticals; Consultancy pertaining to pharmacology; Consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics; Development of new technology for others in the field of pharmacology; Development of pharmaceutical preparations and medicines; Drug discovery services; Executing of chemical analyses; Genetic mapping for scientific purposes; Genetic testing for scientific research purposes; Genetic testing of laboratory animals for research purposes; Laboratory analysis in the field of pharmacology; Laboratory research services relating to pharmaceuticals; Medical and scientific research in the field of cancer treatment and diagnosis; Medical and scientific research in the field of pharmacology; Medical and scientific research information in the field of pharmacology; Medical and scientific research, namely, conducting clinical trials for others; Medical laboratory services; Medical research; Medical research services in the field of cancer; Performance of chemical analyses; Pharmaceutical drug development services; Pharmaceutical product evaluation; Pharmaceutical products development; Pharmaceutical research and development; Pharmaceutical research services; Providing laboratory research services in the field of gene expression, namely, cancer biology; Providing medical and scientific research information in the field of clinical trials; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Providing medical testing services and information in the field of cancer research and disease classification; Research and development in the pharmaceutical and biotechnology fields; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Research in the field of chemistry; Research on the subject of pharmaceuticals; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; Scientific investigations for medical purposes; Scientific laboratory services; Scientific research; Scientific research and development; Scientific research for medical purposes in the area of cancerous diseases; Scientific research in the field of genetics and genetic engineering; Testing, inspection or research of pharmaceuticals, cosmetics or foodstuff; Working on and evaluation of chemical analyses; Working on and evaluation of chemical syntheses | SECTION 8 - CANCELLED | Aug 1, 2011 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by SUMITOMO DAINIPPON PHARMA CO., LTD.
- Other trademarks owned by Tolero Pharmaceuticals, Inc.
- Other trademarks owned by Tolero Pharmaceuticals, Inc.
- Other trademarks owned by Tolero Pharmaceuticals, Inc.
- Other trademarks in Class 042
- Similar marks named TOLERO PHARMACEUTICALS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Dec 10, 2021 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Jun 9, 2020 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Feb 9, 2018 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 9, 2018 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Dec 13, 2017 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Jun 9, 2015 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 24, 2015 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 24, 2015 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 4, 2015 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 14, 2015 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Feb 13, 2015 | ALIE | ASSIGNED TO LIE | — |
| Jan 27, 2015 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 27, 2015 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jan 27, 2015 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jan 27, 2015 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jan 27, 2015 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jan 27, 2015 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 15, 2014 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 11, 2014 | NWAP | NEW APPLICATION ENTERED | — |